Signaling pathways and targeted therapies for psoriasis | RTCL.TV

Psoriasis Treatment Update: A Focus on Targeted Therapies

Psoriasis and beyond: targeting the IL-17 pathway

Fine-Tuning the JAK/STAT Pathway in Psoriasis

Refining Treatment Targets for the Management of Psoriasis

The Current State of Psoriasis Treatment with Targeted Therapy

The TYK2 Pathway as a Novel Nonbiologic Oral Therapeutic Option in Moderate to Severe Psoriasis

Innovations in Systemic Treatments for Psoriasis | Andrew Blauvelt, MD, MBA | United States

Advances in Anti-Cytokine Therapy: New Pathways (IL 12/23, IL17, IL23)

Update in Treatment of Psoriatic Arthritis

Understanding the use of IL12/IL23 targeted biologics

Addressing Disease Progression in Psoriatic Arthritis: Optimizing Targeted Therapies

Psoriasis: Translating Current and Emerging Therapies into Enhanced Management Strategies

Decoding genetic skin disorders: lessons and new technologies

Recent Advances in the Treatment of Moderate-to-Severe Psoriasis: A Focus on Targeted Agents

CYTOKINE SIGNALING Th17 Pathway

Advances in Psoriatic Arthritis and Spondyloarthropathy

Research Update: Newly Approved Therapies for Psoriasis

Drug Targeting in Psoriatic Arthritis - Bruce Kirkham, MD

Treatment of Psoriatic Disease